MoS2 is frequently reported as an effective photocatalytic promoter; however, its explicit roles in improving photo-activity are rarely discussed. In this regard, current study aims to unravel the promotional roles of MoS2, specifically to ZnCdS in degrading tetracycline (TC) under visible light irradiation. ZnCdS/MoS2 derived from photo-deposition approach manifested a large interface with ZnCdS-encapsulating-MoS2 architecture. Alongside MoS2-deposition, the photocatalytically-inert oxide phases of ZnCdS were concurrently eliminated, enabling better photo-responsiveness to visible light. This comes with the closure of energy gap of ZnCdS (evidenced experimentally and theoretically); however, did not weaken its reductive capability due to its unaltered conduction band position. On the other hand, though the valence band of ZnCdS would slightly elevate with MoS2-embedment, its oxidative power is still adequate for direct oxidation of TC. This, therefore, explains TC removal which predominantly assisted by photo-holes and •OH radical (produced from O2-reductive pathway). Electronically-speaking, MoS2 embedment helps in lowering the impedance of ZnCdS, facilitating charges separation while lengthening their lifetimes in photoreaction. Meanwhile, MoS2-modification could also improve TC adsorption onto ZnCdS; this helps in improving utilization of photo-charges while facilitate TC degradation. These benefitting attributes of MoS2, therefore, permitted 458% activity improvements to ZnCdS, realizing 40.93 × 10-5 ppm min-1 TC removal under visible light.
* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.